ICER plans to assess the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp) for the treatment of multiple myeloma. An FDA decision on idecabtagene vicleucel is expected in early 2021. A BLA submission for ciltacabtagene autoleucel is expected by end of 2020.

Interventions of Interest:

  • idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio)
  • ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp)
  • Belantamab mafodotin (Blenrep™, GlaxoSmithKline)

Date of review: April 2021

For questions, please contact Liis Shea, Program Manager, at lshea@icer.org.

View the Key Stakeholders List.